References
- Davis C., Rohatiner A., Lim J., Whelan J., Oza A., Amess J., Love S., Stead E., Lister T. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period. Br J Haematol 1993; 83: 404–11
- Keating M., Kantarjian H., Smith T., Estey E., Walters R., Andersson B., Beran M., McCredie K., Freiretch E. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin One 1989; 7(8)1071–9
- Hiddemann W., Martin W., Sauerland C., Heinecke A., Buchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of retreatment by Thioguanine, cytosine Arabinoside, and Daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 1990; 4: 184–8
- Rees J., Swirsky D., Gray R., Hayhoe F. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; 1236–41
- Welborn J., Lewis J., Meyers F. Impact of rein-duction regimens on the clinical course of adult acute nonlymphocytic leukemia. Leukemia 1988; 2: 711–6
- Herzig R., Wolff S., Lazarus H., Phillips G., Karanes C., Herzig G. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361–9
- Vogler W. R., McCarley D. L., Stagg M., Bartolucci A. A., Moore J., Martelo O., Omura G. A. A phase III trial of high-dose cytarabine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia a Southeastern Cancer Study Group trial. Leukemia 1994; 8(11)1847–53
- Estey E., Kornblau S., Pierce S., Kantarjian H., Beran M., Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 1996; 88(2)756
- Smits P., Schoots L., De Pauw B., De Witte T., Holdrinet R., Janssen J., Haanen C. Prognostic factors in adult patients with acute leukemia at first relapse. Cancer 1987; 1631–4
- Smith I., Clink H., Gerken M., McElwain T. VP-16–213 in acute myelogenous leukemia. Postgraduate Medical Journal 1976, 52: 66–70
- Bennet J., Lymann G., Cassilith P., Glick J., Oken M. A phase II trial of VP-16–213 in adults with refractory acute myelogenous leukemia. Am J Clin Path 1984; 7: 471–3
- Varini M., Cavilli F. Etoposide in the treatment of acute leukemia in adults. Cancer Treat Rev 1982; 9: 59–62
- Sanz M. A., Bonanad S., Sanz G. F., Martin G. Carboplatin and etoposide in acute myeloid leukemia. Leukemia 1994; 8: 1599–600
- Vogler W., Lazarus H., Winton E., et al. A phase II clinical trial of carboplatin in relapsed and refractory leukemia by the Eastern Cooperative Oncology Group. [Abstract]. Blood 1990; 76(Supplement 1)332
- Martinez J. A., Martin G., Sanz G. F., Sempere A., Jarque I., de la Rubia J., Sanz M. A. A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphocytic leukemia. J Clin One 1991; 9: 39–43
- Lee E., Egorin M., Van Echo D., Cohen A., Tait N., Schiffler C. A. Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia. JNCI 1988; 80: 131–5
- Muller M., Rosenstein B., Subramaman D. Recruitment of topoisomerase I following DNA damage in human cells. Proc AACR 1996; 37: 637
- Lee E., Reck K., Carter C., Hodges S., Schiffer C. A. A phase I trial of carboplatin and etoposide given as continuous infusion to adults with leukemia. Leukemia 1993; 7(10)1500–3